About

About FeroptoCure Inc FerroptoCure Inc. is at the forefront of developing revolutionary anticancer drugs that leverage ferroptosis, a novel form of cell death induced by oxidative stress. The suppression of ferroptosis is closely linked to the onset, growth, and spread of various cancers, as well as the development of resistance to conventional anticancer treatments. This makes ferroptosis a critical and promising target for next-generation cancer therapies. Our innovative approach focuses on disrupting the anti oxidative systemin which suppress ferroptosis in cancer. This allows us to target cancer cells with unprecedented precision and efficacy. By addressing this mechanism, our drugs have the potential to treat a wide range of cancers, including those that are resistant to current therapies. Our anti-cancer drugs have demonstrated anti-tumor effects in various types of cancer and holds great promise as a highly valuable advancement. Furthermore, our approach involves the use of small molecule compounds, which eliminates the need for specialized and costly techniques. These offer hope to patients with limited treatment options. FerroptoCure has already entered the Phase I clinical trial mainly targeting triple-negative breast cancer, a significant milestone that underscores the potential of our drug candidates to transform the oncology landscape. By combining cutting-edge science with a commitment to improving patient outcomes, we aim to deliver groundbreaking solutions that bring significant innovation to cancer treatment. Based on the results of our ongoing trials, we are prepared to rapidly expand development on a global scale, targeting not only Japan but global market. The market potential for our ferroptosis-based therapy is enormous. The global oncology drug market is expected to surpass $500 billion by 2030, with hard-to-treat cancers representing a significant share. The TNBC market alone is projected to exceed $3 billion by 2027, and by expanding our approach to broader indications, FerroptoCure has the potential to capture a 200 billion-dollar market worldwide. With global clinical trials planned, we are actively securing **regulatory approvals (FDA/EMA) and strategic partnerships. Backed by cutting-edge science, FerroptoCure is set to redefine cancer treatment and bring a breakthrough cure to patients worldwide.